•  
  •  
 

DOI

http://dx.doi.org/10.18590/mjm.2016.vol2.iss1.4

Abstract

ABSTRACT

Objective: To describe the use of denosumab as an option for treating bisphosphonate-resistant humoral hypercalcemia of malignancy.

Methods: We present the clinical history and laboratory findings of a patient with a review of related literature.

Results: A 62 year-old male with stage IV laryngeal squamous cell carcinoma and lung metastases had multiple hospital admissions for asymptomatic hypercalcemia. The patient had no known bone metastases. His laboratory data showed a high calcium level, a low level of intact PTH and a high level of PTHrP, which confirmed the diagnosis of humoral hypercalcemia of malignancy. There was atypically an elevated level of 1,25(OH)2D. The patient was treated with fluids, prednisone, calcitonin, and bisphosphonates. Hypercalcemia was refractory to bisphosphonate treatment as well as other modalities. Denosumab treatment was then added. Denosumab along with bisphosphonate produced an added effect on lowering calcium levels.

Conclusion: Denosumab provides potentially a new treatment option for bisphosphonate refractory humoral hypercalcemia of malignancy, especially in the presence of high PTHrP and 1,25(OH)2D.

Abbreviations: PTH: Parathyroid Hormone, PTHrP: Parathyroid Hormone Related Peptide, HHM: Humoral Hypercalcemia of Malignancy. 1,25(OH)2D: 1,25-dihydroxyvitamin D. TSH: Thyroid stimulating hormone. RANKL: Receptor activator of nuclear factor kappa-B ligand.

Key words: hypercalcemia, squamous cell carcinoma, malignancy, denosumab, bisphosphonate,1,25-dihydroxyvitamin D.

This material presented in part at the American Association of Clinical Endocrinologists, 23rd Annual Scientific and Clinical Congress, No. 633, 2014.

Conflict(s) of Interest

N/A

References with DOI

1. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373-379.

2. Baron R, Ferrari S, Russell RG.Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011; 48:677-692. https://doi.org/10.1016/j.bone.2010.11.020

3. Khoury N, Chang J, Gru AA, et al. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab. J Clin Endocrinol Metab. 2012 Sep;97:3051-3015. https://doi.org/10.1210/jc.2012-1792

4. Vellanki P, Lange K, Elaraj D, et al. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J Clin Endocrinol Metab. 2014;99 :387-390. https://doi.org/10.1210/jc.2013-3031

5. Boikos SA, Hammers HJ. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia. J Clin Oncol. 2012;30:e299.O https://doi.org/10.1200/jco.2012.41.7923

6. Hu MI, Glezerman I, Leboulleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013;105:1417–1420. https://doi.org/10.1093/jnci/djt225

7. Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for Treatment of Hypercalcemia of Malignancy. J Clin Endocrinol & Metab. 2014; 99 :3144-3152. https://doi.org/10.2147/odrr.s78991

8. Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab. 2012;97:2947–2956.

9. Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes. 2011;18:339–346. https://doi.org/10.1097/med.0b013e32834b4401

10. Rosol TJ, Capen CC: Mechanism of cancer- induced hypercalcemia. Lab Invest. 1992; 67: 680-702.

11. Schilling T, Pecherstorfer M, Blind E, et al. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab.1993; 76: 801–803. https://doi.org/10.1210/jc.76.3.801

12. Horwitz MJ, Tedesco MB, Sereika SM, et al. Continuous infusion of parathyroid hormone versus parathyroid hormone-related protein in humans: discordant effects on 1,25(OH)2 vitamin D and prolonged suppression of bone formation. J Bone Min Res. 2005;20:1792–1803.

13. Horwitz MJ, Stewart AF, Malignancy-associated hypercalcemia and medical management. Chapter 63. In: Jameson JL, De Groot LJ, eds. Endocrinology: Adult and Pediatric. 6th ed. Philadelphia, PA: Saunders Elsevier, 2010; 1198-1211.

14. Lumachi F, Brunello A, Roma A, et al. Cancer- induced hypercalcemia. Anticancer Res. 2009; 29: 1551-1556. https://doi.org/10.1097/00002820-198606000-00005

15. Stewart AF, Horst R, Deftos LJ, et al. Biochemical evaluation of patients with cancer-associated hypercalcemia:evidence for humoral and nonhumoral groups. N Engl J Med. 1980; 303:1377–1383. ttps://doi.org/10.1056/nejm198012113032401

16. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558–567.

17. Gurney H, Grill V, Martin TJ: Parathyroid hormone- related protein and response to pamidronate in tumor-induced hypercalcemia. Lancet. 1993; 341: 1611–1613. https://doi.org/10.1016/0140-6736(93)90756-7

18. Walls J, Ratcliffe WA, Howell A, et al. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone- related protein. Br J Cancer. 1994;70: 169–172. https://doi.org/10.1038/bjc.1994.270

19. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082-3092 https://doi.org/10.1016/j.ejca.2012.08.002

Share

COinS